Imaging Biometrics Ltd (LSE:IBAI, FRA:5Y1) has set out a clearer strategic direction for 2026, signalling that it will step back from further clinical development of its experimental cancer drug and concentrate instead on growing its imaging software business.
The London-listed group said it no longer believes it is in shareholders’ interests to proceed to a second-stage, or phase II, clinical trial of gallium maltolate, a compound it has been studying as a potential treatment for aggressive brain cancers.
Mid-stage studies are typically larger and far more expensive than early safety evaluations, as they are designed to test whether a treatment actually works.
Imaging Biometrics sponsored a small phase I in early 2022, looking at oral gallium maltolate in patients with recurrent glioblastoma, a fast-growing form of brain tumour.
While one patient remains on treatment, enrolment into the study was formally closed in November. The company said the researchers involved are now preparing the results for submission to a peer-reviewed medical journal.
Despite deciding not to take the drug further itself, the company stressed that the work already done still has value.
Imaging Biometrics continues to hold two orphan drug designations, two rare paediatric disease designations and a Fast Track designation from the US Food and Drug Administration.
Such labels are granted to treatments aimed at small patient populations and can offer regulatory incentives, including quicker review processes, if a drug is developed in the future.
The company also pointed to an external study it is watching closely: the GABRIEL paediatric trial, which is investigating gallium maltolate in rare childhood brain tumours at Children's Hospital of Wisconsin.
Imaging Biometrics said it is not formally involved in that trial, but will monitor progress for any scientific insights that could shape future thinking around the compound.
For now, however, management is prioritising nearer-term commercial opportunities.
The group said its imaging business, which provides advanced software to help clinicians analyse medical scans, is showing stronger commercial performance, wider clinical adoption and growing recognition for its technological differentiation.
“This decision reflects a disciplined commitment to focus,” the company said, arguing that concentrating resources on imaging allows it to build momentum, strengthen its financial foundations and improve its long-term outlook.
In plain terms, Imaging Biometrics is choosing to back the part of the business that already generates revenue and customer demand, rather than continuing to fund a costly and uncertain drug development programme.